Consumer Services · NSE: MEDPLUS
Medplus Health Services
Q2 FY27 earnings highlights, from the results presentation
Q2 FY27 · From the investor presentation
- M.Cap
- ₹7,432Cr
- P/E
- 35.2×
- 1Y return
- −20.82%
- From 52W high
- −39.5%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 2,037 | 1,679 | +21.3% | 1,880 | +8.4% |
| EBITDA | 170 | 149 | +14.2% | 133 | +27.6% |
| EBITDA margin | 8.3% | 8.9% | -51 bps | 7.1% | +126 bps |
| PBTProfit before tax | 70 | 69 | +1.8% | 42 | +67.5% |
| Net profit | 56 | 56 | +1.0% | 33 | +69.0% |
| EPS (₹) | 4.72 | 4.62 | +2.2% | 2.76 | +71.0% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
More figures from the presentation
“• 219 gross additions”
“• 101 net additions beyond Tier-One”
“312 Store Net Additions Stores > 12 months”
“• 441 gross additions”
“• 226 net additions beyond Tier-One”
“MedPlus has a curated private label range of 1750+ SKUs. From these, we will:”
In short
- 01Q2 FY27 revenue was Rs 20,371.1m, up 21.3% year on year; PAT was Rs 560.7m, up 1.0%.
- 02Gross margin was 25.1%, 110 bps lower year on year.
- 03Pharmacy operating EBITDA margin was 4.4% and diagnostics 23.8% in Q2 FY27.
- 04Net store additions were 166 in the quarter, taking the network to 5,642 stores.
- 05Stores older than 12 months grew revenue 13.2% with 11.7% store-level EBITDA margin.
- 06Operating cash flow was 37.7% of operating EBITDA; closing cash and investments Rs 5,439m.
Segments
Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA margin: pharmacy 4.4%, diagnostics 23.8%, company 4.8%
Slides · p. 18
Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA margin: pharmacy 4.4%, diagnostics 23.8%, company 4.8%
“Operating EBITDA 3.2% 17.8% -10.6% 3.5% 4.4% 23.8% -8.6% 4.8%”
Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA: pharmacy Rs 885.4m, diagnostics Rs 97.9m
Slides · p. 18
Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA: pharmacy Rs 885.4m, diagnostics Rs 97.9m
“Operating EBITDA 588.1 65.9 (2.8) 651.2 885.4 97.9 (2.2) 981.1”
Stores > 12 months: Older stores: 13.2% revenue growth over Q2 FY26
Slides · p. 5
Stores > 12 months: Older stores: 13.2% revenue growth over Q2 FY26
“• 13.2% revenue growth over Q2FY26”
Stores > 12 months: H1 FY27: older stores grew revenue 14.9%
Slides · p. 7
Stores > 12 months: H1 FY27: older stores grew revenue 14.9%
“• 14.9% revenue growth over H1FY26”
Plan to grow further in cities with market leadership, Metro and Tier-One first
Slides · p. 10
Plan to grow further in cities with market leadership, Metro and Tier-One first
“• Further grow in cities where we have market leadership. Metro and Tier - One followed”
Margins and costs
Gross margin 25.1% in Q2 FY27, lower by 110 bps yoy
Slides · p. 5
Gross margin 25.1% in Q2 FY27, lower by 110 bps yoy
“25.1% GM%, lower by 110 bps yoy,”
Stores > 12 months: Stores older than 12 months: 11.7% store level EBITDA margin
Slides · p. 5
Stores > 12 months: Stores older than 12 months: 11.7% store level EBITDA margin
“• 11.7% Store Level EBITDA margin”
Private label share 0.6% lower than in Q2 FY26
Slides · p. 5
Private label share 0.6% lower than in Q2 FY26
“0.6% decrease in private label over”
Q2 FY27 finance costs Rs 366.2m, up 27.1% yoy
Slides · p. 17
Q2 FY27 finance costs Rs 366.2m, up 27.1% yoy
“Finance Costs (288.2) (332.7) (366.2) 27.1% 10.1% (561.8) (698.9) 24.4%”
Q2 FY27 rental expenses Rs 807.5m, up 19.7% yoy
Slides · p. 17
Q2 FY27 rental expenses Rs 807.5m, up 19.7% yoy
“Rental Expenses 674.9 773.9 807.5 19.7% 4.3% 1,316.7 1,581.4 20.1%”
Debt and working capital
Operating cash flow was 37.7% of operating EBITDA in Q2 FY27
Slides · p. 5
Operating cash flow was 37.7% of operating EBITDA in Q2 FY27
“• 37.7% OCF/ Operating EBITDA”
Closing cash, bank balance and investments of Rs 5,439m
Slides · p. 5
Closing cash, bank balance and investments of Rs 5,439m
“₹ 5,439m closing cash, bank balance”
Rs 358m withdrawn from fixed deposits/investments during the quarter
Slides · p. 23
Rs 358m withdrawn from fixed deposits/investments during the quarter
“3. Additionally, during the quarter we have withdrawn ₹358m from fixed deposit/investments”
Net working capital at 54 days as of Sep-26
Slides · p. 22
Net working capital at 54 days as of Sep-26
“NWC (days) 53 53 53 54 54”
H1 FY27 operating cash flow was 99.4% of operating EBITDA
Slides · p. 7
H1 FY27 operating cash flow was 99.4% of operating EBITDA
“• 99.4% OCF/ Operating EBITDA”
Other
Q2 FY27 revenue Rs 20,371.1m, up 21.3% yoy and 8.4% qoq; H1 revenue up 21.6%
Slides · p. 17
Q2 FY27 revenue Rs 20,371.1m, up 21.3% yoy and 8.4% qoq; H1 revenue up 21.6%
“Revenue 16,793.3 18,796.0 20,371.1 21.3% 8.4% 32,219.6 39,167.1 21.6%”
Q2 FY27 PAT Rs 560.7m, up 1.0% yoy; H1 FY27 PAT Rs 892.4m, down 8.8%
Slides · p. 17
Q2 FY27 PAT Rs 560.7m, up 1.0% yoy; H1 FY27 PAT Rs 892.4m, down 8.8%
“PAT 555.0 331.7 560.7 1.0% 69.1% 978.5 892.4 -8.8%”
Company operating EBITDA Rs 981.1m in Q2 FY27, up 10.7% yoy and 50.7% qoq
Slides · p. 17
Company operating EBITDA Rs 981.1m in Q2 FY27, up 10.7% yoy and 50.7% qoq
“Operating EBITDA 886.5 651.2 981.1 10.7% 50.7% 1,614.6 1,632.3 1.1%”
Stores > 12 months: Older stores: 72.0% store level operating ROCE
Slides · p. 5
Stores > 12 months: Older stores: 72.0% store level operating ROCE
“• 72.0% Store Level Operating ROCE”
Store level unit economics with ROCE of over 70%
Slides · p. 4
Store level unit economics with ROCE of over 70%
“with ROCE of over 70%”
Sources
- Investor presentation, Q2 FY27 Filed 27 Oct 2026 · 27 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

